DRUG DEVELOPMENT FOR TOXOPLASMOSIS ASSOCIATED WITH AIDS

发展治疗学基础研究与发展处 艾滋病司，作为其使命的一部分，促进研究 与发现和开发治疗糖尿病的新疗法有关的努力 HIV感染和机会性感染(OIS)的治疗 与艾滋病有关。在美国，10%到40%的艾滋病患者 各州有患弓形体脑炎(TE)的风险 潜在弓形虫感染的重新激活。血栓栓塞症的当前治疗方法 已被证明有毒、昂贵或只有部分有效。发展中的 新的、更有效的治疗药物是至关重要的，但它 受限于L)潜在临床前测试的难度 治疗2)普遍缺乏制药业研究和 这一领域的发展，以及3)相对缺乏关于 控制慢性和潜伏性的生物和免疫过程 弓形虫感染。 这份合同将为快速评价提供重要资源 弓形虫脑炎的新疗法及其继续 弓形体脑炎体内和体外模型的建立 和潜伏感染。该项目将补充 该部门通过以下方式刺激OI药物发现和开发的战略 为TE提供体内和体外测试系统，这些系统不容易 可供科学界使用。这样的资源将允许NIAID 为研究人员发起的药物发现提供关键支持 TE，以刺激私营部门对新药的赞助，表演 用于多种用途的药物和药物组合的比较研究 OI预防研究，并为OI提供必要的信息 临床研究设计。

The Developmental Therapeutics Branch, Basic Research and Development Program, Division of AIDS, as part of its mission, facilitates research efforts related to the discovery and development of new therapies for the treatment of HIV infection and the opportunistic infections (OIs) associated with AIDS. Between 10 and 40 % of AIDS patients in the United States are at risk of developing toxoplasmic encephalitis (TE) through reactivation of latent Toxoplasma infections. Current therapies for TE have proven toxic, expensive, or only partially effective. Development of new, more efficacious therapeutic agents is of utmost importance, yet it has been limited by l) the difficulty of preclinical testing of potential therapies 2) the general lack of pharmaceutical industry research and development in this area, and 3) the relative lack of information on the biological and immunologic processes that control chronic and latent Toxoplasma infections. This contract will provide a critical resource for expeditious evaluations of new therapies for toxoplasmic encephalitis and the continued development of in vivo and in vitro models for toxoplasmic encephalitis and latent infection. This project will complement other activities in the Division's strategy to stimulate OI drug discovery and development by providing in vivo and in vitro test systems for TE that are not readily available to the scientific community. Such a resource will allow NIAID to provide critical support for investigator-initiated drug discovery for TE, to stimulate private sector sponsorship of new drugs, to perform comparative studies of drugs and drug combinations to be used in multiple OI prophylaxis studies, and contribute essential information for the design of clinical studies.